SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Terry D. who wrote (3084)5/22/1999 5:55:00 PM
From: shero  Read Replies (1) of 3702
 
Terry, please forward this to rosberY.

Yes, we've heard how "hard it is to make a positive statement when 75% of the patients have died," and I don't buy that scenario. Its a matter of perspective.

Let's examine the facts:
1) GBM and AA are rapidly progressing diseases that are always fatal.
2) A phase one study isn't really designed to produce results but to determine safety of the drug (This is one for Maurice--determining safety of a drug that treats an always fatal disease.)
3) Half the patients received much less than a full theraputic dose.
4) The other half received only one dose.
5) The phase two allows two doses.
6) The FDA was sufficiently impressed to allow some of the phase two patients who are newly diagnosed to receive this new treatment as a "frontline" treatment.
7) 25% of the patients are alive and stable when they should have been dead.

I see no trouble fitting any or all of those seven points into a very positive statement. ANY QUESTIONS, TUSTIN?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News